HVEM Products for Immuno-Oncology Research
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
AMSBIO has introduced a new range of Herpes Virus Entry Mediator (HVEM) products for use in immuno-oncology research.
These new products will be of great interest to researchers studying TNFR family members such as CD137 (4-1BB), GITR, OX40, CD27, and other co-stimulatory proteins involved in B and T cell development, immune activation, and antitumor immune responses.
The AMSBIO range includes a suite of HVEM products including an HVEM/LIGHT cellular assay, recombinant LIGHT, BTLA, and HVEM proteins, HVEM and LIGHT expressing cell lines, as well as a BTLA:HVEM [Biotinylated] Inhibitor Screening Assay Kit to study these pathways.
HVEM, also known as CD270 or TNFSFR14 (Tumor Necrosis Factor Receptor Superfamily Member 14), is a cell surface receptor expressed on many immune cells, including T cells. HVEM plays a key role in herpes simplex virus infection. The interaction between HVEM and the viral protein Glycoprotein D (gD) is one of the first steps of herpes simplex virus (HSV) entry into the cell. Recently HVEM has also become an important immuno-oncology target after researchers discovered that HVEM is involved in the induction of apoptosis of tumor cells.
When HVEM interacts with a protein known as LIGHT (TNFSF14, CD258), it creates a co-stimulatory signal that activates lymphoid cells and amplifies the immune response. This means HVEM/LIGHT binding combines immune system amplification with a pro-apoptotic effect, providing a double punch against cancer, and therefore making it a particularly promising target for cancer drug discovery.
HVEM also can bind to a protein called BTLA (CD272, IgSF), which negatively regulates T-cell immune responses. Thus, HVEM can act as a molecular switch, either activating or inhibiting the immune response, depending which ligand it binds.
These new products will be of great interest to researchers studying TNFR family members such as CD137 (4-1BB), GITR, OX40, CD27, and other co-stimulatory proteins involved in B and T cell development, immune activation, and antitumor immune responses.
The AMSBIO range includes a suite of HVEM products including an HVEM/LIGHT cellular assay, recombinant LIGHT, BTLA, and HVEM proteins, HVEM and LIGHT expressing cell lines, as well as a BTLA:HVEM [Biotinylated] Inhibitor Screening Assay Kit to study these pathways.
HVEM, also known as CD270 or TNFSFR14 (Tumor Necrosis Factor Receptor Superfamily Member 14), is a cell surface receptor expressed on many immune cells, including T cells. HVEM plays a key role in herpes simplex virus infection. The interaction between HVEM and the viral protein Glycoprotein D (gD) is one of the first steps of herpes simplex virus (HSV) entry into the cell. Recently HVEM has also become an important immuno-oncology target after researchers discovered that HVEM is involved in the induction of apoptosis of tumor cells.
When HVEM interacts with a protein known as LIGHT (TNFSF14, CD258), it creates a co-stimulatory signal that activates lymphoid cells and amplifies the immune response. This means HVEM/LIGHT binding combines immune system amplification with a pro-apoptotic effect, providing a double punch against cancer, and therefore making it a particularly promising target for cancer drug discovery.
HVEM also can bind to a protein called BTLA (CD272, IgSF), which negatively regulates T-cell immune responses. Thus, HVEM can act as a molecular switch, either activating or inhibiting the immune response, depending which ligand it binds.
